| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6012ce2ccf64fbc34ba201c9f11ada92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_067a3c5fff599aa564fefd4d03be8fde |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-16143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-10343
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-861
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18 |
| filingDate |
2015-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f68d76cb562d57a6fd9d982d098f568a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7f9876bbcd4895bac8a06e30ccec770 |
| publicationDate |
2017-01-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3110953-A1 |
| titleOfInvention |
Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| abstract |
Replicating recombinant adenovirus vectors derived from human adenovirus serotype 26 or human adenovirus serotype 35 are described. The replicating recombinant adenovirus vectors have attenuated replicative capacity as compared to that of the corresponding wild-type adenovirus. They can be used for stable expression of heterologous genes in vivo. Also described are compositions and methods of using these recombinant adenovirus vectors to induce an immune response in a subject, and vaccinate a subject against an immunogenic human immunodeficiency virus (HIV) infection. |
| priorityDate |
2014-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |